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Purpose: To investigate whether variants in the lysyl oxidase-like 1 (LOXL1) gene are associated with exfoliation
glaucoma (XFG) and primary open-angle glaucoma (POAG) in an ancestral population from South Africa.
Methods: Black South African subjects with XFG, POAG, and age matched unaffected controls were recruited from the
St. John Eye Hospital in Soweto, Johannesburg, South Africa, using standard clinical examination techniques. Fifty
individuals were collected for each of the three groups: XFG, POAG, and normal controls. The complete coding region of
LOXL1 was sequenced using the PCR-based Sanger method. The allele frequencies of the identified sequence variants
were compared between XFG or POAG and controls using Fisher’s exact test.
Results: A large number of coding variants were identified, including rs1048661 (R141L), rs3825942 (G153D), S159A,
S161L, rs41435250 (A320A), rs13329473 (F489F), and T567A. The allele frequencies of both rs3825942 and rs1048661
differed significantly between the XFG and control subjects from South Africa (p=5.2×10−13 and 1.7×10−5, respectively).
The G allele for rs1048661 (encoding arginine) was the risk allele which is similar to other populations. The A allele of
rs3825942 (encoding aspartic acid) was the risk allele, in sharp contrast to the G allele (encoding glycine) reported in
multiple other populations. There was no significant difference in the allele frequencies of coding variants in LOXL1
between POAG and control subjects.
Conclusions: This represents the first genetic association study of LOXL1 in an ancestral African population with XFG.
We have confirmed the association between variants of LOXL1 and XFG. To date, the G allele of the major susceptibility
variant rs3825942 has consistently been shown in multiple populations to increase the risk of XFG. Surprisingly, we have
found a strong association with the opposite allele in the South African population. This suggests that other as yet unknown
causal variants of LOXL1 contribute to the genetic risk of XFG.
Glaucoma is a heterogeneous group of disorders that are
defined by a shared characteristic of progressive loss of retinal
ganglion cells, optic nerve cupping, and visual field loss.
Glaucoma is the most common cause of irreversible blindness
worldwide and primary open-angle glaucoma (POAG) is the
single most common type [1]. POAG is a particular problem
in people of African descent where it is more common, occurs
at  a  younger  age  and  progresses  more  rapidly  [2-4].
Exfoliation glaucoma (XFG) is the most common identifiable
cause of open-angle glaucoma [5]. XFG occurs in the context
of  exfoliation  syndrome  (XFS),  a  systemic  condition
characterized  by  pathological  deposits  of  microfibrillar
material within the anterior segment of the eye as well as in
various extraocular tissues [6]. The prevalence of XFS and
XFG  varies  widely  in  different  populations.  XFS  is  most
Correspondence to: R. Rand Allingham, M.D., Duke University Eye
Center, Durham, NC, 27710; Phone: (919) 684-2975; FAX: (919)
681-8267; email: rand.allingham@duke.edu
common  in  Greek  [7]  and  Nordic  populations  with  a
prevalence of over 10% in Iceland that increases with age
[8]. It is uncommon in African Americans [9,10], and virtually
non-existent in West Africa [11]. However, XFG is the cause
of  approximately  16  to  20%  of  glaucoma  in  black  South
Africans [12,13]. This ancestral population of speakers of
southern Bantu languages can be subdivided into three distinct
linguistic groups (Nguni, Sotho/Tswana, and Venda), but they
are relatively similar genetically [14].
In 2007 Thorleifsson et al. [15], in their genome-wide
association study, found a strong association between XFG/
XFS and common sequence variants in the lysyl oxidase-like
1 (LOXL1) gene on chromosome 15q24.1. Three significantly
associated  single  nucleotide  polymorphisms  (SNPs)  were
identified: two nonsynonymous coding SNPs, rs1048661 and
rs3825942, located in exon 1 of LOXL1, and an intronic SNP,
rs2165241,  located  in  intron  1  [15].  These  findings  have
subsequently  been  replicated  in  numerous  populations
globally [16-34], but to date there has not been a study of
Molecular Vision 2010; 16:705-712 <http://www.molvis.org/molvis/v16/a80>
Received 22 March 2010 | Accepted 14 April 2010 | Published 21 April 2010
© 2010 Molecular Vision
705LOXL1 in an ancestral African population with XFG or XFS.
Of the reported non-synonymous LOXL1 risk variants only
rs3825942,  which  codes  for  an  amino  acid  change  from
glycine to aspartic acid at position 153 (G153D), has been
consistently associated with XFS and XFG [35]. Interestingly,
this risk variant is the common variant in all populations
studied to date and has an allele frequency that ranges between
80 and 90% in non-African populations [35]. In contrast,
opposite alleles at the rs1048661 coding change have been
found to be associated with an increased XFG risk in different
populations [35]. The purpose of this study was to examine
the role of LOXL1 sequence variants in a black South African
population with XFG and POAG.
METHODS
Study participants: This study adhered to the tenets of the
Declaration of Helsinki. The research protocol was approved
by  the  University  of  the  Witwatersrand  Human  Research
Ethics  Committee  (Johannesburg,  South  Africa;  protocol
number M080817). Southern African black participants with
clinically diagnosed XFG or POAG and unaffected southern
African control subjects were recruited from the St. John Eye
Hospital  in  Soweto,  Johannesburg,  South  Africa.  Written
informed  consent  was  obtained  from  all  participants.  The
home language of participants and that of their parents and
grandparents was used to establish their ethnic affiliation. All
participants underwent a standardized detailed ophthalmic
examination by the same ophthalmologist (S.E.I.W.). The
examination included measurement of intraocular pressure
(IOP) by applanation, slit lamp biomicroscopy, gonioscopy,
and dilated pupil examination of the lens and fundus. Subjects
with XFG were defined as those with clinical evidence of
exfoliation material on the pupil margin, anterior lens surface,
and the presence of glaucomatous optic neuropathy and visual
field loss. Subjects with POAG had evidence of glaucomatous
optic neuropathy and visual field loss with open angles on
gonioscopy and no evidence for a secondary cause for the
glaucoma and no clinical evidence of exfoliation. Southern
African subjects with normal anterior segment and optic nerve
examination,  an  IOP  of  less  than  18  mmHg  and  without
clinical signs of exfoliation were recruited as control subjects.
DNA analysis: Genomic DNA was extracted using a salting
out procedure from nucleated cells from the venous blood
samples of all subjects [36]. Primers flanking the entire coding
sequence  of  LOXL1  were  either  designed  with  Primer3
software  [37]  or  as  reported  by  Fan  et  al.  [34].  Primer
sequences are provided in Table 1. A pair of primers was also
designed to sequence a potential promoter variant rs16958477
based on a recent study [38]. All the primers were designed
to cover at least 30 base pairs into the intronic region to cover
potential  sequence  variants  affecting  exon  splicing.  All
sequencing  was  performed  using  appropriately  selected
primers  and  conditions  optimized  in  a  standard  fashion.
Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA)
was used for all the PCR reactions. The PCR reactions were
performed in ThermoHybaid MBS 02, 02S, and 02G PCR
machines (Thermo Scientific, Waltham, MA). PCR 1d was
run with a three-stage program (94 °C for 3 min; then 94 °C
for 5 s, 61 °C for 30 s, 72 °C for 45 s over 40 cycles, then
72  °C  for  6  min  over  1  cycle).  The  PCR  program  for
sequencing  rs16958477  was  similar  but  with  a  60  °C
annealing  step  and  only  over  35  cycles.  The  other  PCR
reactions were performed using a touchdown program (94 °C
for 3 min; then 94 °C for 5 s, 65 °C for 30 s, 72 °C for 1 min
over 2 cycles; 94 °C for 5 s, 63 °C for 30 s, 72 °C for 1 min
over 2 cycles; 94 °C for 5 s, 61 °C for 30 s, 72 °C for 1 min
TABLE 1. LIST OF PCR PRIMERS FOR LOXL1 (LYSYL OXIDASE-LIKE 1) EXON SEQUENCING IN SOUTH AFRICAN BLACK INDIVIDUALS WITH OR WITHOUT EXFOLIATION
GLAUCOMA.
LOXL1
exon Forward primer sequence Reverse primer sequence
PCR
product
size (bp) Covered genomic region*
Promoter CCACCAACAAAGAGGGTGTG ACCGCCTGTGGGCCTTAC 597 chr15:72,005,330–72,005,926
Exon1a TCCCAGCCTGTTGCTTATTC AGGCCTGGTGGACAGAGAG 326 chr15:72,005,836–72,006,161
Exon1b AAGCAAGGAGCCTTCCTGTC GCACCCGGGAGCTACTCT 330 chr15:72,006,074–72,006,403
Exon1c1 GCAGGTGTACAGCTTGCTCA ACACGAAACCCTGGTCGTAG 464 chr15:72,006,324–72,006,787
Exon1c2 GCTCAACTCGGGCTCAGA GAACTGCTGCGGGTAGGA 370 chr15:72,006,339–72,006,708
Exon1d CTCCTACCCGCAGCAGTTC GGTACTCGGGCAGCTCTTC 227 chr15:72,006,690–72,006,916
Exon1e CGACCAGGGTTTCGTGTACT AGGTAGGGCGGCTCCAG 402 chr15:72,006,771–72,007,172
Exon1f AGCAGGCCTACCCTGACC GCCTCCAGGAAGTTCTAAGGA 340 chr15:72,007,037–72,007,376
Exon2 CCAACCTGATGCTCTCAATG CACAGCTAGGCTGGGTTCTG 248 chr15:72,022,182–72,022,429
Exon3 CATGCTGGGTTCTGGTGTC GAGCTCAGGCACCAAGGTC 271 chr15:72,025,749–72,026,019
Exon4 CAGGGAAGACTAGGCCCTCT CTGTGAGCAGAGCTGAGTGG 324 chr15:72,026,413–72,026,736
Exon5 CCAGAAACTCCTGAAGGTGG GGGACATTGGACATGAACATC 232 chr15:72,027,121–72,027,352
Exon6 TTACCACCTTCTCTGGTGAGC TCCCCAGGCAGGAAAGG 248 chr15:72,028,773–72,029,020
Exon7 CCCTCATTGACCCACTGTCT GCATGCAGAGCCACAGAGTA 356 chr15:72,031,193–72,031,548
The asterisk indicates the covered genomic regions were based on the March 2006 human reference sequence (NCBI Build 36.1).
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over 2 cycles; 94 °C for 5 s, 57 °C for 30 s, 72 °C for 1 min
over 2 cycles; 94 °C for 5 s, 55 °C for 30 s, 72 °C for 1 min
over 30 cycles; and 72 °C for 3 min). The final annealing
temperature was raised to 56 °C for the 1c1, 1c2, and 1e primer
reactions. Mg2+ concentration was 2.0 mM for exon 7 PCR
and 1.5 mM for all other reactions. Sequencing reactions were
performed  using  BigDye®  Terminator  v3.1  Cycle
Sequencing Kits and run on the ABI 3730 DNA analyzer
(Applied  Biosystems,  Foster  City,  CA).  All  the  sequence
analysis  was  done  by  using  the  Sequencher  4.9  software
package (Gene Codes, Ann Arbor, MI). Allele frequencies at
rs1048661 and rs3825942 were confirmed by bi-directional
sequencing with two sets of primers (1c1 and 1c2).
Statistical  analysis:  Hardy–Weinberg  equilibrium  (HWE)
was examined separately among cases and control subjects
using the exact test. The Fisher’s exact test was used to test
the allelic association of the SNPs with XFG and POAG. The
Bonferroni correction was used to adjust for multiple testing.
Taking  into  account  15  independent  tests,  the  corrected
significance threshold was 0.003.
TABLE 2. DEMOGRAPHIC AND CLINICAL FEATURES OF STUDY SUBJECTS.
Clinical feature XFG subjects n=50 POAG subjects n=50 Control subjects n=50
Age at recruitment (years–mean±SD) 70.4±8.6 57.0±10.1 68.4±9.6
Age at diagnosis (years–mean±SD) 68.0±9.0 54.5±10.6 N/A
Sex
- Female 20 27 20
- Male 30 23 30
Tribal affiliation
- Pedi 1 10 5
- Sotho 9 6 6
- Tswana 11 4 11
- Venda 3 1 2
- Xhosa 7 4 3
- Zulu 12 24 14
- Swazi 2 1 2
- Ndebele 2 0 1
- Tsonga 3 0 6
IOP at diagnosis (mmHg–mean±SD) 30.6±12.9 33.3±9.4 13.4±2.5
Cup-disc ratio at diagnosis (mean±SD) 0.8±0.2 0.9±0.1 0.4±0.1
TABLE 3. LIST OF CODING VARIANTS IDENTIFIED FROM LOXL1 EXON SEQUENCING IN SOUTH AFRICAN BLACK INDIVIDUALS WITH OR WITHOUT EXFOLIATION
GLAUCOMA.
Location Nucleotide
sequence change*
Amino acid
change
SNP ID Allele Allele frequency
controls (N)
Allele
frequency
XFG (N) p value
Promoter g.62,481A>C - rs16958477 A 0.862 (47) 0.947 (47) 0.08
Exon 1 c.98G>A - Novel G 0.990 (48) 1.000 (48) 1.00
Exon 1 c.727G>T R141L rs1048661 G 0.810 (50) 0.990 (50) 1.7×10−5‡
Exon 1 c.763G>A G153D rs3825942 G 0.620 (50) 0.130 (50) 5.2×10−13‡
Exon 1 c.780T>G S159A Novel T 0.920 (50) 0.980 (50) 0.10
Exon 1 c.787C>T S161L Novel C 0.970 (50) 1.000 (50) 0.25
Exon1 c.939G>A V212M Novel G 0.990 (50) 0.980 (50) 1.00
Exon 1 c.1,157C>T P284P Novel C 0.990 (48) 1.000 (48) 1.00
Exon 1 c.1,265G>T A320A rs41435250 G 1.000 (50) 0.990 (49) 0.49
Intron 3 g.82,933C>T - Novel C 0.917 (48) 0.963 (41) 0.23
Exon 4 c.1,772C>T F489F rs13329473 C 0.970 (50) 0.980 (50) 1.00
Intron 4 g.83,628G>A - rs74026313 G 0.730 (50) 0.470 (50) 0.00028
Intron 5 g.84,278G>A - Novel G 0.990 (48) 1.000 (48) 1.00
Exon 6 c.2,004A>G T567A Novel A 0.989 (47) 1.000 (48) 0.50
Exon 7 c.2,130G>C - rs8818 G 0.543 (47) 0.521 (48) 0.77
Exon 7 c.2,196C>T - rs3522 T 0.674 (43) 0.830 (47) 0.023
The asterisk indicates that nucleotides are numbered as in GenBank accession number BC015090   (coding) and AC108137
(genomic). The double dagger indicates significant after correction for multiple testing.
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‡RESULTS
Fifty XFG patients, fifty POAG patients, and fifty control
individuals were recruited into this study. All XFG patients,
POAG  patients  and  controls  were  self-identified  as  black
South Africans speaking a range of southern Bantu languages,
including Pedi, Sotho, Tswana, Venda, Xhosa, Zulu, Swazi,
Ndebele, and Tsonga. A summary of the clinical phenotypes
are recorded in Table 2.
All  DNA  samples  were  sequenced  using  Sanger’s
method.  Identified  LOXL1  sequence  variants  are  listed  in
Table  3  for  XFG  and  control  individuals.  The  relative
positions of the identified variants are shown in Figure 1. All
SNPs were in HWE (p>0.01) in the control group. The most
Figure 1. Identified LOXL1 sequence variants in black South African population. Known SNPs are identified by their rs number designation.
Novel coding variants reported as resulting amino acid change. Novel non-coding variants reported as base pair change. Sequence positions
are based upon GenBank accession number BC015090 (coding) and AC108137 (genomic). In the image, boxes indicate exons and straight
lines indicate introns.
TABLE 4. GENETIC ASSOCIATION OF COMMON LOXL1 CODING CHANGES WITH EXFOLIATION GLAUCOMA (XFG) IN THE BLACK SOUTH AFRICA POPULATION.
 
rs1048661G allele rs3825942 G allele
Group Frequency p value* OR** Frequency p value* OR**
Control 0.810     0.620    
XFG 0.990 1.7×10−5 23.2 (3.0–177.2) 0.130 5.2×10−13 0.092 (0.045–0.19)
The asterisk indicates Fisher’s exact test comparing to controls. The double asterisk indicates Odds ratio (95% confidence
interval).
TABLE 5. LIST OF CODING VARIANTS IDENTIFIED FROM LOXL1 EXON SEQUENCING IN SOUTH AFRICAN BLACK INDIVIDUALS WITH PRIMARY OPEN-ANGLE GLAUCOMA.
Location Nucleotide
sequence change*
Amino acid
change
SNP ID Allele Allele Frequency
Controls (N)
Allele Frequency
POAG (N)
p value
Exon 1 c.727G>T R141L rs1048661 G 0.810 (50) 0.870 (50) 0.34
Exon 1 c.763G>A G153D rs3825942 G 0.620 (50) 0.600 (50) 0.88
Exon 1 c.780T>G S159A Novel T 0.920 (50) 0.920 (50) 1.00
Exon 1 c.787C>T S161L Novel C 0.970 (50) 0.990 (50) 0.62
Exon 1 c.1,265G>T A320A rs41435250 G 1.000 (50) 0.966 (44) 0.10
Intron 3 g.82,933C>T - Novel C 0.917 (48) 0.880 (46) 0.47
Exon 4 c.1,772C>T F489F rs13329473 C 0.970 (50) 0.980 (50) 1.00
Intron 4 g.83,628G>A - rs74026313 G 0.730 (50) 0.740 (50) 1.00
Intron 5 g.84,278G>A - Novel G 0.990 (48) 0.979 (48) 1.00
Exon 6 c.2,004A>G T567A Novel A 0.989 (47) 0.979 (48) 1.00
Exon 7 c.2,130G>C - rs8818 G 0.543 (47) 0.553 (48) 1.00
Exon 7 c.2,196C>T - rs3522 T 0.674 (43) 0.620 (47) 0.53
The asterisk indicates that nucleotides are numbered as in GenBank accession number BC015090   (coding) and AC108137
(genomic).
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coding  changes  rs1048661  and  rs3825942  and  XFG
(p=1.7×10−5  and  p=5.2×10−13,  respectively),  as  shown  in
Table 4. Importantly, the risk allele for rs3825942 was not the
G allele described in other populations, but the A allele. While
rs74026313, located in the fourth intron, was also associated
with  XFG  (p=2.8×10−4).  These  risk  variants  remained
significant  after  correction  for  multiple  testing  (p≤0.003).
Another  coding  change,  rs3522  located  in  exon  7  was
nominally associated with XFG (p=0.02) but did not survive
correction  for  multiple  testing.  No  association  with
rs16958477  was  found  (p=0.08;  Table  3).  This  sequence
change is located in the promoter region of LOXL1 and has
been reported to be associated with XFG.
The functional impact of the two novel, but rare, exon 1
non-synonymous variants S159A and S161L were assessed in
silico using PolyPhen and predicted to be benign (PSIC score
difference  0.079)  and  possibly  damaging  (PSIC  score
difference 1.685), respectively.
Several  coding  variants  including  rs1048661  and
rs3825942 were also identified in South African black POAG
patients,  as  listed  in  Table  5.  No  association  was  found
between any LOXL1 sequence variants and POAG (p>0.05,
Fisher exact test). The allele frequencies for the G allele of
rs1048661 was 0.87 compared to 0.81 for controls (p=0.34)
and for the G allele of rs3825942 was 0.60 compared to 0.58
for controls (p=0.88).
DISCUSSION
LOXL1  is  one  of  the  lysyl  oxidase  group  of  enzymes
consisting of LOX and the LOX- like enzymes 1 to 4. As a
group these enzymes are involved in the first step of the
formation of cross-links in collagen and elastin. LOXL1 binds
to fibulin 5 and tropoelastin at sites of elastogenesis to catalyze
the cross-linking that forms elastin polymers [39]. Exon 1 of
the LOXL1 gene encodes the unique NH2-terminal domain
that is required both for proper enzyme activation and for
substrate recognition and binding. It has been postulated that
genetic variations in LOXL1 in this region may contribute to
the  formation  of  the  pathological  fibrillar  aggregates
accumulating in tissues of patients with XFG [40].
Thorleifsson and coworkers [15] identified significant
associations of XFS/XFG with the non-synonymous coding
changes  rs1048661  and  rs3825942  in  the  Caucasian
population. It has been hypothesized that one or both of these
SNPs  are  causally  involved  in  the  pathobiology  of  XFS
although no evidence beyond genetic association has been
reported to date. However, several recent observations now
argue against this hypothesis. Multiple studies reported that
TABLE 6. SUMMARY OF THE GENETIC ASSOCIATION OF TWO CODING VARIANTS IN LOXL1 GENE WITH XFS/XFG.
  rs1048661G allele   rs3825942 G allele    
Studied
population
Case Control Significant
association
Case Control Significant
association
Reference
Icelandian 0.781 0.651 Yes 0.984 0.847 Yes [15]
Swedish 0.834 0.682 Yes 0.995 0.879 Yes [15]
American 0.819 0.600 Yes 0.986 0.880 Yes [16]
Australian 0.78 0.660 Yes 0.95 0.84 Yes [17]
American 0.787 0.665 Yes 0.939 0.844 Yes [18]
American NA NA NA 1.000 0.856 Yes [19]
American 0.843 0.703 Yes 0.959 0.798 Yes [20]
Austrian 0.841 0.671 Yes 0.994 0.817 Yes [21]
Germany 0.818 0.644 Yes 0.951 0.857 Yes [22]
Italian 0.825 0.693 Yes 1.000 0.821 Yes [22]
Finnish 0.825 0.683 Yes 0.968 0.823 Yes [23]
Germany 0.844 0.660 Yes 0.992 0.856 Yes [24]
Chinese 0.110 0.480 Yes 1.000 0.900 Yes [25]
Japanese 0.036 0.493 Yes 1.000 0.877 Yes [26]
Japanese 0.008 0.460 Yes 1.000 0.857 Yes [27]
Japanese 0.006 0.450 Yes 0.994 0.853 Yes [28]
Japanese 0.005 0.474 Yes 0.995 0.850 Yes [29]
Japanese 0.005 0.497 Yes 0.986 0.863 Yes [30]
Japanese 0.005 0.554 Yes 0.993 0.806 Yes [31]
Indian 0.721 0.634 No 0.923 0.742 Yes [32]
Chinese 0.542 0.444 No 0.992 0.918 Yes [33]
American 0.829 0.719 No 0.988 0.795 Yes [34]
South African 0.990 0.810 Yes 0.130 0.620 Yes This study
In the table, NA indicates not available; LOXL1   indicates lysyl oxidase-like 1; XFS indicates exfoliation syndrome; and XFG
indicates exfoliation glaucoma.
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populations (Table 6) [32-34]. Furthermore, although the G
allele of rs1048661 was associated with an increased XFS/
XFG risk in Caucasian populations, the opposite (T) allele was
associated with an increased risk in the Chinese and Japanese
populations (Table 6) [25-31]. Our finding for rs3825942 in
the South African black population mirrors this previously
reported  result  for  rs1048661.  Further  evidence  against  a
causal role of rs3825942 in XFG stems from reports that this
SNP does not appear to affect LOXL1 gene expression levels
in blood or ocular tissues [15,41] and that it may represent a
conservative substitution based on the in silico prediction
programs  Polymorphism  Phenotyping  (PolyPhen)  and
Sorting Intolerant From Tolerant (SIFT) [34]. Taken together,
these data suggest that other functional risk factors in LOXL1
remain to be identified.
Interestingly,  XFS  and  XFG  are  rarely  found  in  the
African  American  and  West  African  populations  [10,42].
Why XFS is so rare in persons of West African descent is
puzzling, especially in light of a recent report confirming the
presence of major LOXL1 risk variants in these populations
[43].  The  low  XFS/XFG  prevalence  suggests  that  other
genetic  or  environmental  factors,  and  not  just  LOXL1,
contribute to the pathogenesis of this condition. This is the
first association study of LOXL1 in XFG patients performed
in an ancestral African population. We have confirmed the
association of the major non-synonymous coding variants
rs1048661 and rs3825942 with XFS/XFG. However, in the
black South African population, the risk at rs3825942 is the
A allele not the G allele observed to increase risk in all other
reported populations. Interestingly, in contrast to non-African
populations with XFG, for whom the major (more common)
allele confers an increased risk, the allele is the minor allele
in this population. This finding suggests that none of the
currently known sequence variants in LOXL1 may be critical
for the exfoliation phenotype.
In  summary,  this  study  corroborates  the  genetic
association of LOXL1 sequence variants with XFG in a South
African black population and has generated two novel results.
First,  rs3825942  (G153D)  risk  allele  is  reversed  in  this
population  compared  with  non-African  populations
suggesting that this SNP may only be a proxy for the as yet
unknown causal variant(s) in LOXL1. This finding is similar
to  previously  reported  results  for  rs1048661  in  Asian
populations. Second, we did not observe an XFG association
with SNP rs16958477, which was hypothesized to affect the
LOXL1 promoter activity. In light of our study and the work
reported by others, further analysis of the promoter and other
regulatory regions of the LOXL1 gene in the Caucasian, Asian,
and African populations is warranted.
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